Montelukast Viatris

Montelukast, the active ingredient in Montelukast Viatris, is a leukotriene receptor antagonist presented as an oral tablet for oral use. It treats asthma, allergic rhinitis and exercise‑induced bronchoconstriction in adults and children as indicated.

GNH USA supplies Montelukast Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction.

Asthma: provides maintenance therapy that reduces the frequency of symptoms and exacerbations. Allergic rhinitis: relieves nasal congestion, sneezing and itching associated with seasonal allergies. Exercise‑induced bronchoconstriction: prevents bronchospasm triggered by physical activity.

Montelukast is generally well tolerated, but adverse reactions can occur.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Dizziness - Fatigue

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema, or anaphylaxis - Neuropsychiatric events including depression, anxiety, or suicidal thoughts - Elevated liver enzymes - Severe skin reactions such as Stevens‑Johnson syndrome - Eosinophilic granulomatosis with polyangiitis (Churg‑Strauss syndrome) - Hematologic abnormalities

Before initiating therapy, clinicians should consider several safety aspects.

Assess asthma control: ensure patient is on appropriate baseline therapy. Monitor neuropsychiatric symptoms: watch for mood changes or suicidal ideation. Use caution in hepatic impairment: dose adjustment may be required. Review concomitant CYP‑modulating drugs: potential for altered exposure. Avoid in patients with known hypersensitivity to montelukast or excipients. Store at room temperature: keep in the original container, protect from moisture.

Montelukast may interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole) may increase montelukast plasma levels. - Phenobarbital can lower montelukast concentrations, reducing therapeutic effect. - Rifampin may markedly decrease montelukast exposure.

Moderate Interactions (Monitor Closely): - Selective serotonin reuptake inhibitors may heighten neuropsychiatric risk. - Beta‑agonists may produce additive bronchodilation. - Warfarin may experience variable anticoagulant effect; monitor INR.